Alzamend Neuro, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-21$2.43 RISE2026-05-19$1.01 PEAK2026-05-20$1.20 119d | -58.4% 118d | Missed | Missed | — | — | +18.8% 1d | Missed |
DROP2026-01-21$2.43 RISE2026-04-10$0.86 PEAK2026-05-20$1.20 119d | -64.7% 79d | Missed | Missed | — | — | +39.9% 40d | Missed |
DROP2025-10-30$2.61 RISE2026-02-13$1.63 PEAK2026-03-11$2.18 132d | -37.5% 106d | Missed | Missed | — | — | +33.7% 26d | Missed |
DROP2025-09-16$2.62 RISE2025-12-31$1.82 PEAK2026-01-21$2.43 127d | -30.5% 106d | Missed | Missed | — | — | +33.5% 21d | Missed |
DROP2025-07-17$3.42 RISE2025-11-21$1.96 PEAK2026-01-21$2.43 188d | -42.7% 127d | Missed | Missed | — | — | +24.0% 61d | Missed |
DROP2025-06-04$3.97 RISE2025-10-10$2.18 PEAK2025-10-30$2.61 148d | -45.1% 128d | Missed | Missed | — | — | +19.7% 20d | Missed |
DROP2025-03-27$9.90 RISE2025-08-01$2.20 PEAK2025-09-16$2.62 173d | -77.8% 127d | Missed | Missed | — | — | +19.1% 46d | Missed |
DROP2024-11-04$14.85 RISE2025-03-12$6.03 PEAK2025-03-27$9.90 143d | -59.4% 128d | Missed | Missed | — | — | +64.2% 15d | Missed |
DROP2024-03-11$108.00 RISE2024-05-13$45.45 PEAK2024-05-16$58.41 66d | -57.9% 63d | Missed | Missed | — | — | +28.5% 3d | Missed |
DROP2023-09-28$322.65 RISE2024-01-26$72.90 PEAK2024-03-11$108.00 165d | -77.4% 120d | Missed | Missed | — | — | +48.1% 45d | Missed |
DROP2023-08-14$461.70 RISE2023-12-20$75.78 PEAK2024-03-11$108.00 210d | -83.6% 128d | Missed | Missed | — | — | +42.5% 82d | Missed |
DROP2023-06-01$1,043.55 RISE2023-09-26$257.85 PEAK2023-09-28$322.65 119d | -75.3% 117d | Missed | Missed | — | — | +25.1% 2d | Missed |
DROP2023-02-03$958.50 RISE2023-05-19$675.00 PEAK2023-06-01$1,043.55 118d | -29.6% 105d | Missed | Missed | — | — | +54.6% 13d | Missed |
DROP2022-11-22$1,687.50 RISE2023-03-20$499.50 PEAK2023-06-01$1,043.55 191d | -70.4% 118d | Missed | Missed | — | — | +108.9% 73d | Missed |
DROP2022-10-05$1,998.00 RISE2022-12-28$715.50 PEAK2023-02-03$958.50 121d | -64.2% 84d | Missed | Missed | — | — | +34.0% 37d | Missed |
1–15 / 21 1 / 2 | |||||||
No scored news yet for a sentiment trend.
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced encouraging pharmacodynamic findings from a brain magnetic resonance spectroscopy ("MRS") analysis conducted in healthy human subjects (N=6) in a trial conducted at Massachusetts Genera
Potentially Distinct Brain Profile: Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced positive topline data from its first Phase II "Lithium in Brain" clinical trial in healthy human subjects, demonstrating that AL001 meets bioequivalence standards while also showing num
Bioequivalence Confirmed: AL001 delivered 101% of total lithium blood exposure and 97% of peak lithium levels vs. standard lithium carbonateSuperior Brain Penetration: AL001 showed numerically higher lithium
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced the initiation of its Phase II clinical trial evaluating AL001 in patients diagnosed with BD type 1. The trial is being conducted at Massachusetts General Hospital ("MGH") and represents a sig
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major
-SEC Filing
Here is how Allogene Therapeutics (ALLO) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.
Here is how Allogene Therapeutics (ALLO) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.
Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lowers the price target from $42 to $28.
Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(1.96) by 84.65 percent. This is a 91.69 percent increase over losses of $(3.61) per share from
Embecta's Q4 earnings loom as product momentum, global trends and recent strategic gains set the stage for potential top-line support.
Embecta's Q4 earnings loom as product momentum, global trends and recent strategic gains set the stage for potential top-line support.
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced completion of the clinical portion of its first Phase II clinical study of AL001, in healthy human subjects.
Alzamend Neuro, Inc. (NASDAQ:ALZN) on Wednesday announced the completion of the clinical portion of its first Phase 2 clinical study of AL001 in healthy human subjects. ALZN stock is racing ahead of the pack. View the charts here Topline data is expected in the first quarter of 2026. Earlier, the company expected topline results from the first trial by year-end 2025, with follow-up trials in bipolar disorder, major depressive disorder, post-traumatic stress disorder, and Alzheimer's launching th
Alzamend Neuro, Inc. (NASDAQ:ALZN) on Wednesday announced the completion of the clinical portion of its first Phase 2 clinical study of AL001 in healthy human subjects. ALZN stock is racing ahead of the pack. View the charts here Topline data is expected in the first quarter of 2026. Earlier, the company expected topline results from the first trial by year-end 2025, with follow-up trials in bipolar disorder, major depressive disorder, post-traumatic stress disorder, and Alzheimer's launching th
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ALZN | +6.25% | -40.80% | -34.62% | -68.93% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +3.28% | -35.08% | -31.17% | -81.62% |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-03-11 | -0.53 | -0.58 | -9.43% |
| 2025-12-09 | -1.95 | -0.30 | +84.65% |
| 2025-09-10 | -0.69 | -1.28 | -85.51% |
| 2025-07-22 | -2.70 | -9.48 | -251.11% |
| 2025-03-10 | -3.19 | -1.71 | +46.48% |
| 2024-12-11 | -3.42 | -3.60 | -5.26% |
| 2024-09-11 | -21.42 | -11.25 | +47.48% |
| 2024-07-30 | -34.20 | -120.15 | -251.32% |
| 2024-03-25 | -29.25 | -34.20 | -16.92% |
| 2023-12-15 | -60.75 | -39.60 | +34.81% |
| 2023-09-13 | -54.00 | -54.00 | — |
| 2023-07-27 | -60.75 | -40.50 | +33.33% |
| 2023-03-15 | -54.00 | -81.00 | -50.00% |
| 2022-12-12 | -54.00 | -40.50 | +25.00% |
| 2022-09-13 | -94.50 | -40.50 | +57.14% |
| 2022-07-19 | -47.25 | -65.88 | -39.43% |